A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis

A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis

Abstract Background To evaluate the immunomodulating and clinical effects of nilotinib, a tyrosine kinase inhibitor, in a proof-of-concept study in spondyloarthritis (SpA) assessing the mast cell as potential novel therapeutic target in this disease. Methods Twenty eight patients with active periphe...

Full description

Bibliographic Details
Main Authors: Jacqueline E. Paramarta, Maureen C. Turina, Troy Noordenbos, Tanja F. Heijda, Iris C. Blijdorp, Nataliya Yeremenko, Dominique Baeten
Format: Article
Language:English
Published: BMC 2016-10-01
Series:Journal of Translational Medicine
Subjects:
Spondyloarthritis
Nilotinib
Tyrosine kinase inhibitor
Randomized controlled trial
Mast cells
Online Access:http://link.springer.com/article/10.1186/s12967-016-1050-2

Internet

http://link.springer.com/article/10.1186/s12967-016-1050-2

Similar Items